StockData
TransMedics Group, Inc. logo

TransMedics Group, Inc. (TMDX) stock

TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3029% below fair value
$93.91+1.70 (+1.84%)

Close on Nov 17, 2026Market cap $3.26BP/E 24.4Yield 0.00%

Earnings

TransMedics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$203.00M
+41.2% on a year earlier
Adjusted diluted net income per share, Q3 FY2026
$0.51
$0.66 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of TransMedics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$203.00M+41.2%$0.46$0.51Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$189.90M+20.6%$0.41$0.44Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours$173.90M+21.2%$0.20$0.30Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026during market hours$160.80M+32.2%$2.62–Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025during market hours$143.80M+32.2%$0.66–Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025during market hours$157.40M+37.7%$0.92–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours$143.50M+48.1%$0.70–Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025during market hours$121.60M+49.8%$0.19–Release
Q3 FY2024ended Sep 30, 2024Oct 28, 2024during market hours$108.80M+63.9%$0.12–Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024during market hours$114.30M+117.7%$0.35–Release
Q1 FY2024ended Mar 31, 2024Apr 30, 2024during market hours$96.90M+132.9%$0.35–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

TransMedics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
full-year 2026 revenue guidance, excluding PAD Aviationnon-GAAPFY2026$737.00M – $757.00M–NewAug 4, 2026
FY 2026 Revenue (excluding PAD Aviation)non-GAAPFY2026$750.00M – $760.00M–NewNov 5, 2026
FY 2026 Revenue (including PAD Aviation)GAAPFY2026$764.00M – $774.00M–NewNov 5, 2026
revenue guidanceFY2026$727.00M – $757.00M$727.00M – $757.00MReaffirmedMay 5, 2026

Guidance vs results

The last range TransMedics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$595.00M – $605.00M$605.50MΣ4QAbove range

Guidance history

Every forecast TransMedics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026FY 2026 Revenue (including PAD Aviation)FY2026$764.00M – $774.00MNew
Nov 5, 2026FY 2026 Revenue (excluding PAD Aviation)FY2026$750.00M – $760.00MNew
Aug 4, 2026full-year 2026 revenue guidance, excluding PAD AviationFY2026$737.00M – $757.00MNew
May 5, 2026revenue guidanceFY2026$727.00M – $757.00MReaffirmed
Feb 24, 2026total revenueFY2026$727.00M – $757.00MNew
Oct 29, 2025revenue guidanceFY2025$595.00M – $605.00MNew
Jul 30, 2025revenue guidanceFY2025$585.00M – $605.00MRaised
May 8, 2025revenue guidanceFY2025$565.00M – $585.00MRaised
Feb 27, 2025total revenue growthFY2025+20% – +25%New
Feb 27, 2025total revenueFY2025$530.00M – $552.00MNew
Oct 28, 2024growthFY2024+76% – +84%New
Oct 28, 2024revenueFY2024$425.00M – $445.00MReaffirmed
Jul 31, 2024revenue guidanceFY2024$425.00M – $445.00MRaised
Apr 30, 2024revenueFY2024$390.00M – $400.00MRaised
Feb 26, 2024total revenueFY2024$360.00M – $370.00MNew
Nov 6, 2023revenue guidanceFY2023$222.00M – $230.00MRaised
Aug 3, 2023revenueFY2023$180.00M – $190.00MRaised
May 1, 2023revenueFY2023$160.00M – $170.00MRaised
Feb 22, 2023total revenueFY2023$138.00M – $145.00MNew
Nov 3, 2022revenueFY2022$80.00M – $85.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases TransMedics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?